

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mi *et al.*

Appl. No.: 10/553,685 (*U.S. National
Phase of PCT/US2004/008323*)

§371 Date: November 1, 2006

For: **Nogo Receptor Binding Protein**

Confirmation No.: 4041

Art Unit: 1656

Examiner: CARLSON, Karen C.

Atty. Docket: 2159.0440003/EJH/CLD

**Fourth Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(d)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on the accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on October 13, 2009, in connection with the above-captioned application.

Copies of document **FP72** and **NPL97** are submitted herewith.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is a filing under 37 C.F.R. § 1.97(d) and is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. The required fee is provided through online credit card payment authorization in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p). In addition, I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee
deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Cynthia L. DeRenzo
Agent for Applicants
Registration No. 60,789

Date: 2/2/10

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
1076587_1.DOC